Advertisement

Use of prophylactic Saccharomyces boulardii to prevent Clostridium difficile infection in hospitalized patients: a controlled prospective intervention study

  • Jeppe West Carstensen
  • Mahtab Chehri
  • Kristian Schønning
  • Steen Christian Rasmussen
  • Jacob Anhøj
  • Nina Skavlan Godtfredsen
  • Christian Østergaard Andersen
  • Andreas Munk Petersen
Original Article
  • 390 Downloads

Abstract

Clostridium difficile infection (CDI) is a common complication to antibiotic use. Saccharomyces boulardii has shown effect as a prophylactic agent. We aimed to evaluate the efficacy of S. boulardii in preventing CDI in unselected hospitalized patients treated with antibiotics. We conducted a 1 year controlled prospective intervention study aiming to prescribe Sacchaflor (S. boulardii 5 × 109, Pharmaforce ApS) twice daily to hospitalized patients treated with antibiotics. Comparable departments from three other hospitals in our region were included as controls. All occurrences of CDI in patients receiving antibiotics were reported and compared to a baseline period defined as 2 years prior to intervention. Results were analyzed using run chart tests for non-random variation in CDI rates. In addition, odds ratios for CDI were calculated. S. boulardii compliance reached 44% at the intervention hospital, and 1389 patients were treated with Sacchaflor. Monthly CDI rates dropped from a median of 3.6% in the baseline period to 1.5% in the intervention period. S. boulardii treatment was associated with a reduced risk of CDI at the intervention hospital: OR = 0.06 (95% CI 0.02–0.16). At two control hospitals, CDI rates did not change. At one control hospital, the median CDI rate dropped from 3.5 to 2.4%, possibly reflecting the effects of simultaneous multifaceted intervention against CDI at that hospital. The results from this controlled prospective interventional study indicate that S. boulardii is effective for the prevention of CDI in an unselected cohort of mainly elderly patients from departments of internal medicine.

Notes

Funding

The study is financed by internal funding at Copenhagen University Hospital Hvidovre, Denmark.

Compliance with ethical standards

Conflict of interest

All authors declare no conflict of interest.

Ethical approval

The study was a non-randomized intervention study in departments with high frequency of CDI and approved by the hospital director and the hospital administration.

Informed consent

Informed consent by patients was given according to standard treatment procedure and according to Danish law.

References

  1. 1.
    CDC. Biggest Threats | Antibiotic/Antimicrobial Resistance | CDC. CDC (2016). http://www.cdc.gov/drugresistance/biggest_threats.html
  2. 2.
    Chiu Y-H, Lin S-L, Tsai J-J, Lin M-Y (2014) Probiotic actions on diseases: implications for therapeutic treatments. Food Funct 5(4):625–634.  https://doi.org/10.1039/c3fo60600g CrossRefPubMedGoogle Scholar
  3. 3.
    Johnson S, Maziade P-J, McFarland LV et al (2012) Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 16(11):e786–e792.  https://doi.org/10.1016/j.ijid.2012.06.005 CrossRefPubMedGoogle Scholar
  4. 4.
    McFarland LV (2010) Systematic review and meta-analysis of saccharomyces boulardii in adult patients. World J Gastroenterol 16(18):2202–2222.  https://doi.org/10.3748/wjg.v16.i18.2202 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C (1999) Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins a and B in human colonic mucosa. Infect Immun 67(1):302–307PubMedPubMedCentralGoogle Scholar
  6. 6.
    Neut C, Mahieux S, Dubreuil LJ (2017) Antibiotic susceptibility of probiotic strains: is it reasonable to combine probiotics with antibiotics? Med Mal Infect 47(7):477–483.  https://doi.org/10.1016/j.medmal.2017.07.001 CrossRefPubMedGoogle Scholar
  7. 7.
    McFarland LV (2015) Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Antibiot (Basel, Switzerland) 4(2):160–178.  https://doi.org/10.3390/antibiotics4020160 CrossRefGoogle Scholar
  8. 8.
    Goldenberg JZ, Yap C, Lytvyn L et al (2017) Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 12:CD006095.  https://doi.org/10.1002/14651858.CD006095.pub4 PubMedCrossRefGoogle Scholar
  9. 9.
    Anhøj J, Olesen AV (2014) Run charts revisited: a simulation study of run chart rules for detection of non-random variation in health care processes. PLoS One 9(11):e113825.  https://doi.org/10.1371/journal.pone.0113825 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Anhøj J (2015) Diagnostic value of run chart analysis: using likelihood ratios to compare run chart rules on simulated data series. PLoS One 10(3):e0121349.  https://doi.org/10.1371/journal.pone.0121349 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    R Core Team (2017) R: A Language and Environment for Statistical Computing.Google Scholar
  12. 12.
    Wickham H. (2017) Tidyverse: Easily Install and Load the “Tidyverse”. R package version 1.2.1.Google Scholar
  13. 13.
    Anhøj J. (2017) qicharts2: Quality Improvement Charts, R package version 0.2.3.Google Scholar
  14. 14.
    Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D (2015) SQUIRE 2.0 (standards for QUality improvement reporting excellence): revised publication guidelines from a detailed consensus process. Can J Diabetes 39(5):434–439.  https://doi.org/10.1016/j.jcjd.2015.08.001 CrossRefPubMedGoogle Scholar
  15. 15.
    Knudsen JD, Andersen SE (2014) Bispebjerg Intervention Group for the BI. A multidisciplinary intervention to reduce infections of ESBL- and AmpC-producing, gram-negative bacteria at a University Hospital. PLoS One 9(1):e86457.  https://doi.org/10.1371/journal.pone.0086457 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Power M, Wigglesworth N, Donaldson E, Chadwick P, Gillibrand S, Goldmann D (2010) Reducing Clostridium difficile infection in acute care by using an improvement collaborative. BMJ 341:c3359 http://www.ncbi.nlm.nih.gov/pubmed/20659985 CrossRefPubMedGoogle Scholar
  17. 17.
    Ehrhardt S, Guo N, Hinz R et al (2016) Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. Open forum Infect Dis 3(1):ofw011.  https://doi.org/10.1093/ofid/ofw011 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Szajewska H, Kołodziej M (2015) Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 42(7):793–801.  https://doi.org/10.1111/apt.13344 CrossRefPubMedGoogle Scholar
  19. 19.
    Ghantoji SS, Sail K, Lairson DR, Dupont HL, Garey KW (2010) Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 74:309–318.  https://doi.org/10.1016/j.jhin.2009.10.016 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Jeppe West Carstensen
    • 1
  • Mahtab Chehri
    • 1
    • 2
  • Kristian Schønning
    • 2
    • 3
  • Steen Christian Rasmussen
    • 2
  • Jacob Anhøj
    • 4
  • Nina Skavlan Godtfredsen
    • 3
    • 5
  • Christian Østergaard Andersen
    • 2
  • Andreas Munk Petersen
    • 1
    • 2
    • 3
  1. 1.Gastro Unit, Medical DivisionCopenhagen University HospitalHvidovreDenmark
  2. 2.Department of Clinical MicrobiologyCopenhagen University HospitalHvidovreDenmark
  3. 3.Department of Clinical Medicine, Faculty of Health and Medical SciencesCopenhagenDenmark
  4. 4.Centre of Diagnostic EvaluationRigshospitaletCopenhagenDenmark
  5. 5.Department of Pulmonary MedicineCopenhagen University HospitalHvidovreDenmark

Personalised recommendations